The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
In terms of private investments, 2020 was the year of the liquid biopsy.
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.